Benzinga · Aug 17, 2026
Stifel Maintains Hold on Staar Surgical, Lowers Price Target to $28
Stifel analyst Thomas Stephan maintains Staar Surgical (NASDAQ:STAA) with a Hold and lowers the price target from $31 to $28.
ST
NASDAQ · STAA
STAAR Surgical Company
Healthcare · Medical - Instruments & Supplies
$24.64
Up+$0.55 (+2.28%)
Updated Aug 19, 2026, 6:32 AM
SID Score
4.2/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 1.22B
- P/E ratio
- -12.83
- Dividend yield
- 0.00%
- 52-week range
- $15.59 – $35.87
- Volume
- 928.45K
- Avg. volume
- 1.06M
Price performance
STAA price history
1M range · 21 trading sessions · Daily adjusted prices
STAA closed at $24.64 after 21 trading sessions, up 1.52% for the selected period.
- Last close
- $24.64
- Period change
- +1.52%
- Period low
- $22.66
- Period high
- $26.18
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 18, 2026 | $24.07 | $25.025 | $23.75 | $24.64 | 928.45K |
| Aug 17, 2026 | $25.96 | $25.96 | $23.82 | $24.09 | 1.54M |
| Aug 14, 2026 | $25.15 | $26.245 | $24.81 | $26.18 | 993.76K |
| Aug 13, 2026 | $24.08 | $25.58 | $23.25 | $25.33 | 1.86M |
| Aug 12, 2026 | $24.86 | $26.0312 | $24.68 | $25.41 | 1.34M |
| Aug 11, 2026 | $25.50 | $25.75 | $24.73 | $24.94 | 827.1K |
| Aug 10, 2026 | $24.28 | $25.3822 | $24.18 | $25.12 | 804.96K |
| Aug 7, 2026 | $22.98 | $24.26 | $22.89 | $24.21 | 809.32K |
| Aug 6, 2026 | $22.80 | $23.19 | $22.20 | $23.12 | 725.57K |
| Aug 5, 2026 | $23.78 | $23.99 | $22.46 | $22.86 | 1.23M |
| Aug 4, 2026 | $24.44 | $24.60 | $23.88 | $24.12 | 1.39M |
| Aug 3, 2026 | $24.38 | $25.49 | $23.59 | $24.34 | 1.06M |
| Jul 31, 2026 | $24.36 | $24.61 | $23.74 | $24.36 | 1.48M |
| Jul 30, 2026 | $24.125 | $24.33 | $23.475 | $24.22 | 879.19K |
| Jul 29, 2026 | $22.54 | $24.37 | $22.50 | $23.87 | 842.93K |
| Jul 28, 2026 | $22.14 | $23.05 | $21.195 | $22.66 | 1.12M |
| Jul 27, 2026 | $23.21 | $23.825 | $22.88 | $22.95 | 725.12K |
| Jul 24, 2026 | $24.25 | $24.345 | $23.35 | $23.38 | 488.85K |
| Jul 23, 2026 | $24.42 | $24.66 | $23.89 | $24.19 | 460.19K |
| Jul 22, 2026 | $24.27 | $25.00 | $23.33 | $24.71 | 876.1K |
| Jul 21, 2026 | $23.97 | $24.6225 | $23.365 | $24.27 | 1.87M |
Latest STAA news
The latest Smart Investors Daily articles mentioning STAA.
Stock researchCompany · Overview
STAA research
Overview
Company profile and research snapshot.
Company profile
Staar Surgical Co is a manufacturer of lenses. It designs, develops, manufactures, and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. The company also makes lenses that are used in surgery to treat cataracts. The company offers two types of products: Implantable Collamer lenses (ICL) and intraocular lens (IOL). The ICLs are used in refractive surgery and IOLs are used in cataract surgery. The majority of its sales are generated from the ophthalmic surgical product segment.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $29.83
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 17, 2026 | Stifel | Hold | — |
| Aug 13, 2026 | UBS | Sell | — |
| Aug 13, 2026 | Wedbush | Outperform | — |
| Aug 4, 2026 | Wedbush | Outperform | — |
| Jul 28, 2026 | UBS | Sell | — |
News briefing
No generated briefing is available yet.
Benzinga · Aug 13, 2026
UBS Maintains Sell on Staar Surgical, Lowers Price Target to $19
UBS analyst Patrick Wood maintains Staar Surgical (NASDAQ:STAA) with a Sell and lowers the price target from $20 to $19.
Benzinga · Aug 13, 2026
Wedbush Maintains Outperform on Staar Surgical, Lowers Price Target to $37
Wedbush analyst Michael Piccolo maintains Staar Surgical (NASDAQ:STAA) with a Outperform and lowers the price target from $40 to $37.
SeekingAlpha · Aug 12, 2026
STAAR Surgical Company (STAA) Q2 2026 Earnings Call Transcript
STAAR Surgical Company (STAA) Q2 2026 Earnings Call August 12, 2026 5:30 PM EDTCompany ParticipantsConnie Johnson - Director of Investor RelationsWarren...
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
